Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials
Journal of Crohn's and Colitis · 04.11.2024 · 18 (11) · 1780-1794
DOI: 10.1093/ecco-jcc/jjae079 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Crohn's and Colitis, online erschienen am 15.06.2024. Verfasst von Séverine Vermeire und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Janus Kinase Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Background and Aims Etrasimod is an oral, once daily, selective, sphingosine 1-phosphate [S1P]1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis [UC]. This subgroup analysis evaluated the efficacy and safety of etrasimod 2 mg once daily vs placebo by prior biologic/Janus kinase inhibitor [bio/JAKi] exposure in ELEVATE UC 52 and ELEVATE UC 12.
Methods
Pre-defined efficacy endpoints were assessed at Weeks 12 and 52 in ELEVATE UC 52 and Week 12 in ELEVATE UC 12 in bio/JAKi-naïve and -experienced patients, and at Week 12 [pooled] based on prior advanced therapy exposure mechanism.
Results
In the ELEVATE UC 52 and ELEVATE UC 12 analysis populations, 80/274 [29.2%] and 74/222 [33.3%] patients receiving etrasimod and 42/135 [31.1%] and 38/112 [33.9%] patients receiving placebo, respectively, were bio/JAKi-experienced. In both bio/JAKi-naïve and -experienced patients, a significantly greater proportion receiving etrasimod vs placebo achieved clinical remission [p < 0.05] in ELEVATE UC 52 at Weeks 12 [naïve: 30.9% vs 9.7%; experienced: 17.5% vs 2.4%] and 52 [naïve: 36.6% vs 7.5%; experienced: 21.3% vs 4.8%]; in ELEVATE UC 12, this was observed only for bio/JAKi-naïve patients [naïve: 27.7% vs 16.2%, p = 0.033; experienced: 18.9% vs 13.2%, p = 0.349]. Similar patterns were observed for most efficacy endpoints. Among patients with prior anti-integrin exposure [N = 90], a significantly greater proportion achieved clinical response [54.1% vs 27.6%, p = 0.030], but not clinical remission [9.8% vs 3.4%, p = 0.248], with etrasimod vs placebo.
Conclusions
Bio/JAKi-naïve and -experienced patients had clinically meaningful induction and maintenance treatment benefits with etrasimod vs placebo. ClinicalTrials.gov NCT03945188; NCT03996369
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
- Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Gastroenterology, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France.
- INSERM, NGERE, University of Lorraine, F-54000 Vandœuvre-lès-Nancy, France.
- INFINY Institute, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France.
- FHU-CURE, Nancy University Hospital, F-54500 Vandœuvre-lès-Nancy, France.
ORCID-Profile: Séverine Vermeire, Julian Panés, Silvio Danese
Förderung
- Pfizer
Zitieren
APA
Vermeire, S., Sands, B. E., Peyrin-Biroulet, L., D'Haens, G. R., Panés, J., Yarur, A. J., Wolf, D. C., Ritter, T., Schreiber, S., Woolcott, J. C., Modesto, I., Keating, M., Shan, K., Wu, J., Chiorean, M. V., Baert, F., Dubinsky, M. C., Goetsch, M., Danese, S., & Feagan, B. G. (2024). Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. Journal of Crohn's and Colitis, 18(11), 1780-1794. https://doi.org/10.1093/ecco-jcc/jjae079
Vancouver
Vermeire S, Sands BE, Peyrin-Biroulet L, D'Haens GR, Panés J, Yarur AJ, et al. Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. Journal of Crohn's and Colitis. 2024;18(11):1780-1794. doi:10.1093/ecco-jcc/jjae079
BibTeX
@article{Vermeire2024,
author = {Vermeire, Séverine and Sands, Bruce E and Peyrin-Biroulet, Laurent and D'Haens, Geert R and Panés, Julian and Yarur, Andres J and Wolf, Douglas C and Ritter, Timothy and Schreiber, Stefan and Woolcott, John C and Modesto, Irene and Keating, Michael and Shan, Kevin and Wu, Joseph and Chiorean, Michael V and Baert, Filip and Dubinsky, Marla C and Goetsch, Martina and Danese, Silvio and Feagan, Brian G},
title = {Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials},
journal = {Journal of Crohn's and Colitis},
year = {2024},
volume = {18},
number = {11},
pages = {1780--1794},
doi = {10.1093/ecco-jcc/jjae079}
}
EUVIMED